Mirabegron
General
Type : Drug || Not A\/B H target || Adrenergic-Receptor-ligand || Thiazolidine || Sulfur compound
Chemical_Nomenclature : 2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide
Canonical SMILES : C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
InChI : InChI=1S\/C21H24N4O2S\/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16\/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)\/t19-\/m0\/s1
InChIKey : PBAPPPCECJKMCM-IBGZPJMESA-N
Other name(s) : Myrbetriq, Betanis, Betmiga
Target
Families : BCHE
References (6)
| Title : Drug and pro-drug substrates and pseudo-substrates of human butyrylcholinesterase - Masson_2023_Biochem.Pharmacol_218_115910 |
| Author(s) : Masson P , Shaihutdinova Z , Lockridge O |
| Ref : Biochemical Pharmacology , 218 :115910 , 2023 |
| Abstract : Masson_2023_Biochem.Pharmacol_218_115910 |
| ESTHER : Masson_2023_Biochem.Pharmacol_218_115910 |
| PubMedSearch : Masson_2023_Biochem.Pharmacol_218_115910 |
| PubMedID: 37972875 |
| Title : Risk of overactive bladder associated with cholinesterase inhibitors in dementia - Masurkar_2021_J.Am.Geriatr.Soc__ |
| Author(s) : Masurkar PP , Chatterjee S , Sherer JT , Chen H , Johnson ML , Aparasu RR |
| Ref : J Am Geriatr Soc , : , 2021 |
| Abstract : Masurkar_2021_J.Am.Geriatr.Soc__ |
| ESTHER : Masurkar_2021_J.Am.Geriatr.Soc__ |
| PubMedSearch : Masurkar_2021_J.Am.Geriatr.Soc__ |
| PubMedID: 34854475 |
| Title : Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment - Konishi_2019_Biopharm.Drug.Dispos_40_176 |
| Author(s) : Konishi K , Minematsu T , Nagasaka Y , Tabata K |
| Ref : Biopharmaceutics & Drug Disposition , 40 :176 , 2019 |
| Abstract : Konishi_2019_Biopharm.Drug.Dispos_40_176 |
| ESTHER : Konishi_2019_Biopharm.Drug.Dispos_40_176 |
| PubMedSearch : Konishi_2019_Biopharm.Drug.Dispos_40_176 |
| PubMedID: 30985942 |
| Title : Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase - Konishi_2018_Xenobiotica__1 |
| Author(s) : Konishi K , Minematsu T , Nagasaka Y , Tabata K |
| Ref : Xenobiotica , :1 , 2018 |
| Abstract : Konishi_2018_Xenobiotica__1 |
| ESTHER : Konishi_2018_Xenobiotica__1 |
| PubMedSearch : Konishi_2018_Xenobiotica__1 |
| PubMedID: 30301385 |
| Title : Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective beta(3)-adrenoceptor agonist - Takusagawa_2012_Xenobiotica_42_957 |
| Author(s) : Takusagawa S , Yajima K , Miyashita A , Uehara S , Iwatsubo T , Usui T |
| Ref : Xenobiotica , 42 :957 , 2012 |
| Abstract : Takusagawa_2012_Xenobiotica_42_957 |
| ESTHER : Takusagawa_2012_Xenobiotica_42_957 |
| PubMedSearch : Takusagawa_2012_Xenobiotica_42_957 |
| PubMedID: 22509825 |
| Title : Mechanism of eserine action on the hydrolysis of butyrylthiocholine by butyrylcholinesterase - Stojan_1997_J.Enzyme.Inhib_11_199 |
| Author(s) : Stojan J , Pavlic MR |
| Ref : J Enzyme Inhib , 11 :199 , 1997 |
| Abstract : Stojan_1997_J.Enzyme.Inhib_11_199 |
| ESTHER : Stojan_1997_J.Enzyme.Inhib_11_199 |
| PubMedSearch : Stojan_1997_J.Enzyme.Inhib_11_199 |
| PubMedID: 9204388 |